Phenanthriplatin is a leading preclinical anticancer Pt complex distinguished by a phenanthridine ligand that facilitates DNA-targeted covalent binding via intercalation. We report here that Pt(II) complexes incorporating phenanthridine into a chelating, multidentate ligand scaffold exhibit a superior in vitro therapeutic index compared with phenanthriplatin and cisplatin.